WO2009147248A3 - Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases - Google Patents

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases Download PDF

Info

Publication number
WO2009147248A3
WO2009147248A3 PCT/EP2009/056975 EP2009056975W WO2009147248A3 WO 2009147248 A3 WO2009147248 A3 WO 2009147248A3 EP 2009056975 W EP2009056975 W EP 2009056975W WO 2009147248 A3 WO2009147248 A3 WO 2009147248A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequences
polypeptides
virus
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/056975
Other languages
French (fr)
Other versions
WO2009147248A2 (en
Inventor
Anna Hultberg
Bram Maassen
Peter Vanlandschoot
Erik Depla
Catelijne Stortelers
Cornelis Theodorus Verrips
Steven Van Gucht
Jose Melero
Michael John Scott Saunders
Johannes Joseph Wilhelmus De Haard
Robert Anthony Weiss
Nigel James Temperton
Xavier Saelens
Bert Schepens
Alexander Szyroki
Michael Marie Harmsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL09757629T priority Critical patent/PL2285408T3/en
Priority to EP18189511.1A priority patent/EP3424526A1/en
Priority to CN200980130125.3A priority patent/CN102112155B/en
Priority to US12/996,074 priority patent/US9193780B2/en
Priority to EP09757629.2A priority patent/EP2285408B1/en
Priority to ES09757629T priority patent/ES2713864T3/en
Priority to CA2726652A priority patent/CA2726652A1/en
Priority to JP2011512149A priority patent/JP5809557B2/en
Priority to AU2009254501A priority patent/AU2009254501B2/en
Priority to LTEP09757629.2T priority patent/LT2285408T/en
Priority to DK09757629.2T priority patent/DK2285408T3/en
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to HRP20182195TT priority patent/HRP20182195T1/en
Priority to SI200931914T priority patent/SI2285408T1/en
Publication of WO2009147248A2 publication Critical patent/WO2009147248A2/en
Publication of WO2009147248A3 publication Critical patent/WO2009147248A3/en
Anticipated expiration legal-status Critical
Priority to ZA2010/09135A priority patent/ZA201009135B/en
Priority to US14/926,381 priority patent/US9834595B2/en
Priority to US15/785,604 priority patent/US10550174B2/en
Priority to CY20191100039T priority patent/CY1121687T1/en
Priority to US16/528,837 priority patent/US11518799B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
PCT/EP2009/056975 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases Ceased WO2009147248A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
DK09757629.2T DK2285408T3 (en) 2008-06-05 2009-06-05 AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
CN200980130125.3A CN102112155B (en) 2008-06-05 2009-06-05 For the aminoacid sequence of virus envelope protein with for treating the polypeptide comprising it of virus disease
US12/996,074 US9193780B2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP09757629.2A EP2285408B1 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ES09757629T ES2713864T3 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CA2726652A CA2726652A1 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
HRP20182195TT HRP20182195T1 (en) 2008-06-05 2009-06-05 SEQUENCES OF AMINO ACIDS AGAINST Viral Envelope Proteins and Polypeptides Containing the Same for the Treatment of Viral Diseases
EP18189511.1A EP3424526A1 (en) 2008-06-05 2009-06-05 Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies
LTEP09757629.2T LT2285408T (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
PL09757629T PL2285408T3 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against viral envelope proteins and polypeptides containing them for the treatment of viral diseases
AU2009254501A AU2009254501B2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
JP2011512149A JP5809557B2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against viral envelope proteins and polypeptides containing them for the treatment of viral diseases
SI200931914T SI2285408T1 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ZA2010/09135A ZA201009135B (en) 2008-06-05 2010-12-20 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US14/926,381 US9834595B2 (en) 2008-06-05 2015-10-29 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US15/785,604 US10550174B2 (en) 2008-06-05 2017-10-17 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CY20191100039T CY1121687T1 (en) 2008-06-05 2019-01-15 AMINO ACID SEQUENCES TARGETING ENVELOPE PROTEINS OF AN IOY AND POLYPEPTIDES CONTAINING THEM FOR THE THERAPEUTIC TREATMENT OF VIRAL DISEASES
US16/528,837 US11518799B2 (en) 2008-06-05 2019-08-01 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US5905508P 2008-06-05 2008-06-05
US61/059,055 2008-06-05
US9299108P 2008-08-29 2008-08-29
US61/092,991 2008-08-29
US13913008P 2008-12-19 2008-12-19
US61/139,130 2008-12-19
US14465309P 2009-01-14 2009-01-14
US61/144,653 2009-01-14
US17291409P 2009-04-27 2009-04-27
US61/172,914 2009-04-27
US17410809P 2009-04-30 2009-04-30
US61/174,108 2009-04-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/996,074 A-371-Of-International US9193780B2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US14/926,381 Division US9834595B2 (en) 2008-06-05 2015-10-29 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Publications (2)

Publication Number Publication Date
WO2009147248A2 WO2009147248A2 (en) 2009-12-10
WO2009147248A3 true WO2009147248A3 (en) 2010-07-15

Family

ID=41055279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056975 Ceased WO2009147248A2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Country Status (17)

Country Link
US (4) US9193780B2 (en)
EP (2) EP3424526A1 (en)
JP (2) JP5809557B2 (en)
CN (1) CN102112155B (en)
AU (1) AU2009254501B2 (en)
CA (1) CA2726652A1 (en)
CY (1) CY1121687T1 (en)
DK (1) DK2285408T3 (en)
ES (1) ES2713864T3 (en)
HR (1) HRP20182195T1 (en)
HU (1) HUE042053T2 (en)
LT (1) LT2285408T (en)
PL (1) PL2285408T3 (en)
PT (1) PT2285408T (en)
SI (1) SI2285408T1 (en)
WO (1) WO2009147248A2 (en)
ZA (1) ZA201009135B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321344A (en) * 2012-03-30 2015-01-28 勃林格殷格翰国际有限公司 ANG2-binding molecules

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
LT2285408T (en) 2008-06-05 2019-01-25 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
AU2015200057B9 (en) * 2009-06-05 2017-03-09 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) Nanobody constructs for the prevention and/or treatment of respiratory tract infections
PT2438087T (en) * 2009-06-05 2017-08-04 Ablynx Nv HUMAN RESPIRATORY SYNCHRONOUS (HRSV) TRIVALENT NANOBODY CONSTRUCTIONS FOR THE PREVENTION AND / OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
DK2533761T3 (en) 2010-02-11 2019-06-24 Ablynx Nv METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF AEROSOLS
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33826A (en) * 2010-12-22 2012-07-31 Abbott Lab UNION PROTEINS WITH TRIVARIABLE DOMAINS AND ITS USES
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2880791A1 (en) * 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
PH12021553014A1 (en) 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US9624272B2 (en) 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
PL2970449T3 (en) * 2013-03-15 2020-04-30 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
JP2016522168A (en) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド Anti-IL-4 antibody and bispecific antibody and use thereof
EP3035970A1 (en) * 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
KR20160079818A (en) * 2013-11-25 2016-07-06 옥스포드 바이오테라퓨틱스 리미티드 Antibodies anti matriptase for the treatment of cancer
US10561805B2 (en) * 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
JP7001474B2 (en) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド Non-immunogenic single domain antibody
MY186585A (en) 2015-02-05 2021-07-28 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
EP3277706A1 (en) * 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
MY192870A (en) 2015-06-18 2022-09-13 Univ Gent Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3124042A1 (en) 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
CA2991634C (en) * 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
JP2017036258A (en) * 2015-08-07 2017-02-16 パナソニックＩｐマネジメント株式会社 Antibodies that bind to influenza virus
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERIAL ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELINE BINDING PROTEINS
WO2018209304A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
US11505601B2 (en) 2017-10-11 2022-11-22 Nanjing Legend Biotech Co., Ltd Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
MX2020003915A (en) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc TRISPECIFIC PROTEINS AND METHODS OF USE.
CN112262215B (en) * 2018-04-23 2025-03-18 美国卫生和人力服务部 Chimeric vector
BR112020023330A2 (en) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. binding portion for conditional activation of immunoglobulin molecules
CN108794626B (en) * 2018-06-18 2021-10-12 上海大学 Polypeptide and gold nanobody capable of targeting HIV envelope protein gp120
CN108640978A (en) * 2018-06-20 2018-10-12 上海大学 Specifically bind the polypeptide of albumen gp120 and its application on inhibition of HIV
WO2020029860A1 (en) * 2018-08-09 2020-02-13 北京智仁美博生物科技有限公司 Bispecific antibody against rabies virus, and application thereof
JP7190675B2 (en) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 Antibody and complex that bind to norovirus, detection device and detection method using the same
JP7190674B2 (en) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 Antibody and complex that bind to norovirus, detection device and detection method using the same
CN109097341B (en) * 2018-08-28 2021-09-24 青岛农业大学 A replication-deficient recombinant influenza virus expressing both HA and HEF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3116292A1 (en) 2018-10-25 2020-04-30 Km Biologics Co., Ltd. Modified cmv gb protein and cmv vaccine including same
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
KR20220063148A (en) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. composition
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
EP4100055A2 (en) * 2020-02-06 2022-12-14 Vib Vzw Corona virus binders
CN115768463A (en) 2020-02-21 2023-03-07 哈普恩治疗公司 FLT 3-binding proteins and methods of use
CN111393512B (en) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 Polypeptide for inhibiting influenza virus and application thereof in preparation of drugs for preventing and treating influenza virus infection
JP7512413B2 (en) * 2020-03-31 2024-07-08 ビオテウス・インコーポレイテッド Anti-PD-L1 and PD-L2 antibodies and their derivatives and uses
CN116194083B (en) * 2020-04-20 2025-01-24 华润生物医药有限公司 Anti-coronavirus antibodies and their uses
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
AU2021271016A1 (en) * 2020-05-12 2023-01-19 The Regents Of The University Of California SARS-CoV2 neutralizing single domain antibody constructs
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
CA3189896A1 (en) * 2020-08-19 2022-02-24 Yi Shi Coronavirus nanobodies and methods for their use and identification
WO2022072550A2 (en) * 2020-09-29 2022-04-07 Academia Sinica Clec2 fusion protein and uses thereof
US20240109963A1 (en) * 2020-11-16 2024-04-04 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
CN112851811B (en) * 2021-01-28 2022-08-09 姜国胜 CD44V6 nano antibody and application thereof as leukemia research reagent
JP2022165899A (en) * 2021-04-20 2022-11-01 株式会社デンソー Conjugate
CN113234151B (en) * 2021-06-08 2022-02-15 皖南医学院第一附属医院（皖南医学院弋矶山医院） Development of a CAR-NK based on a trimeric nanobody targeting the S protein of SARS-CoV2 virus
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof
EP4594348A1 (en) * 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
AR131494A1 (en) 2022-12-23 2025-03-26 Ablynx Nv PROTEIN-BASED CONJUGATION VEHICLES
TW202448926A (en) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 Polypeptides binding to the neonatal fc receptor
CN116375852B (en) * 2023-03-10 2024-02-02 华南农业大学 Recombinant fluorescent nano antibody and application thereof in preparation of rabies virus detection reagent
CN116751284B (en) * 2023-06-13 2024-06-04 康元医疗科技(大连)有限公司 Nanobody, polypeptide containing nanobody and application of polypeptide
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
CN116987194B (en) * 2023-09-26 2023-12-26 江西乐成欣生生物技术研究有限责任公司 Anti-idiotype nano antibody of mimic epitope peptide of human ST2 antigen and application thereof
CN117683137B (en) * 2023-12-04 2024-09-17 江苏省农业科学院 Recombinant bispecific nanoantibodies targeting Newcastle disease virus and H9 subtype avian influenza virus and preparation method and application thereof
TW202543670A (en) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 Protein-based conjugation carriers for intranuclear delivery
CN117843801B (en) * 2023-12-29 2024-08-02 北京贝来药业有限公司 Novel antibodies and downstream products targeting interleukin family members
CN117986360B (en) * 2024-02-01 2024-08-27 生物岛实验室 Specific antibody of IL18 protein and preparation method and application thereof
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026060159A1 (en) * 2024-09-13 2026-03-19 Gilead Sciences, Inc. Vhhs against hsv and uses of the same
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
CN119978135B (en) * 2025-01-02 2025-11-21 生物岛实验室 Specific antibodies against Sumo-tagged proteins, their preparation methods and applications
CN119462912B (en) * 2025-01-15 2025-08-19 中国人民解放军军事科学院军事医学研究院 Nanometer antibody of anti-ebola virus VP40 protein and application thereof in virus detection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065057A1 (en) * 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
WO2003051912A2 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2003105894A1 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized liquid anti-rsv antibody formulations
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP2096121A1 (en) * 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
EP0977590A4 (en) 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
DK1144616T4 (en) 1999-01-19 2009-03-30 Unilever Nv Method for producing antibody fragments
US6133571A (en) * 1999-04-26 2000-10-17 Lockheed Martin Corporation Resonant cavity field enhancing boundary
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AR030019A1 (en) 1999-05-18 2003-08-13 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THE SAME, A PROCEDURE FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A NUCLEIC ACID ISOLATED MOLECULA, A RECOMBINANT PLASMIDE, A HOSPED DIFFERENT USE OF A MUSCLE
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (en) 2001-09-13 2009-01-21 株式会社抗体研究所 Camel antibody library production method
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
ES2374068T3 (en) 2002-12-03 2012-02-13 Ucb Pharma, S.A. TEST TO IDENTIFY ANTIBODY PRODUCTION CELLS.
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough Treatment for acne vulgaris and method of use
ES2385829T3 (en) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Methods to obtain antibodies
EP1737971B1 (en) * 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
KR101151957B1 (en) 2004-07-22 2012-06-01 로저 킹돈 크레이그 binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUSES AND METHODS OF PRODUCING THE VACCINES THEREFOR
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP4976376B2 (en) * 2005-04-08 2012-07-18 メディミューン，エルエルシー Antibodies against mammalian metapneumovirus
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2667466A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
LT2285408T (en) * 2008-06-05 2019-01-25 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
PT2387583T (en) 2009-01-14 2018-12-24 Ablynx Nv PULMONARY ADMINISTRATION OF SINGLE IMMUNOGLOBULIN VARIABLE AREAS AND CONSTRUCTIONS
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
PT2438087T (en) 2009-06-05 2017-08-04 Ablynx Nv HUMAN RESPIRATORY SYNCHRONOUS (HRSV) TRIVALENT NANOBODY CONSTRUCTIONS FOR THE PREVENTION AND / OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
WO2011064382A1 (en) * 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065057A1 (en) * 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
WO2003051912A2 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2003105894A1 (en) * 2002-06-14 2003-12-24 Medimmune, Inc. Stabilized liquid anti-rsv antibody formulations
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP2096121A1 (en) * 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOLLIGER PHILIPP ET AL: "ENGINEERED ANTIBODY FRAGMENTS AND THE RISE OF SINGLE DOMAINS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 9, 1 September 2005 (2005-09-01), pages 1126 - 1136, XP008076746, ISSN: 1087-0156 *
JAIN ET AL: "Engineering antibodies for clinical applications", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 307 - 316, XP022116341, ISSN: 0167-7799 *
SOURIAU CHRISTELLE ET AL: "Recombinant antibodies for cancer diagnosis and therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 2, 1 April 2003 (2003-04-01), pages 305 - 318, XP009097848, ISSN: 1471-2598 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321344A (en) * 2012-03-30 2015-01-28 勃林格殷格翰国际有限公司 ANG2-binding molecules
CN104321344B (en) * 2012-03-30 2017-11-21 勃林格殷格翰国际有限公司 Ang2 binding molecules

Also Published As

Publication number Publication date
EP2285408A2 (en) 2011-02-23
DK2285408T3 (en) 2019-02-04
CA2726652A1 (en) 2009-12-10
US9193780B2 (en) 2015-11-24
LT2285408T (en) 2019-01-25
JP2015156867A (en) 2015-09-03
EP3424526A1 (en) 2019-01-09
CN102112155B (en) 2016-08-10
SI2285408T1 (en) 2019-02-28
HRP20182195T1 (en) 2019-02-22
US20160152693A1 (en) 2016-06-02
US20190077847A1 (en) 2019-03-14
ZA201009135B (en) 2012-06-27
US9834595B2 (en) 2017-12-05
US20110182897A1 (en) 2011-07-28
US10550174B2 (en) 2020-02-04
AU2009254501B2 (en) 2014-07-31
US11518799B2 (en) 2022-12-06
CN102112155A (en) 2011-06-29
AU2009254501A1 (en) 2009-12-10
HUE042053T2 (en) 2019-06-28
EP2285408B1 (en) 2018-10-24
CY1121687T1 (en) 2020-07-31
JP5809557B2 (en) 2015-11-11
US20200123233A1 (en) 2020-04-23
PL2285408T3 (en) 2019-05-31
PT2285408T (en) 2019-02-01
JP2011521662A (en) 2011-07-28
ES2713864T3 (en) 2019-05-24
WO2009147248A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2012088461A3 (en) Linker peptides and polypeptides comprising same
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
ES2379283T3 (en) Serum albumin binding proteins
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2011133886A3 (en) Production of heteromultimeric proteins
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
EA201100070A1 (en) RV2386C TUBERCULOSIC PROTEIN, COMPOSITIONS AND THEIR APPLICATIONS
EA201200515A1 (en) POLYPEPTIDES AND THEIR APPLICATION
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2008093058A3 (en) Peptides and their use
EA201100071A1 (en) NEW COMPOSITIONS AND METHODS
WO2009097530A3 (en) Peptides that target dorsal root ganglion neurons
HK1206763A1 (en) Charged nutritive fragments, proteins and methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980130125.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757629

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2726652

Country of ref document: CA

Ref document number: 2009757629

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009254501

Country of ref document: AU

Ref document number: 2011512149

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11/CHENP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009254501

Country of ref document: AU

Date of ref document: 20090605

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12996074

Country of ref document: US